News coverage about Acceleron Pharma (NASDAQ:XLRN) has trended somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acceleron Pharma earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6046299662433 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

XLRN has been the subject of a number of research analyst reports. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. CIBC lowered shares of Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. Morgan Stanley reduced their price target on shares of Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, June 13th. Finally, FBR & Co set a $63.00 price target on shares of Acceleron Pharma and gave the stock a “buy” rating in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $42.81.

Acceleron Pharma (XLRN) traded down 1.136% during mid-day trading on Thursday, reaching $37.865. 162,769 shares of the company traded hands. The stock’s 50-day moving average price is $36.78 and its 200-day moving average price is $31.63. The firm’s market cap is $1.46 billion. Acceleron Pharma has a one year low of $23.07 and a one year high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. During the same period in the previous year, the business earned ($0.59) EPS. The firm’s revenue was down 3.1% compared to the same quarter last year. Analysts forecast that Acceleron Pharma will post ($2.70) earnings per share for the current fiscal year.

In related news, CFO Kevin F. Mclaughlin sold 16,000 shares of Acceleron Pharma stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total transaction of $614,560.00. Following the transaction, the chief financial officer now owns 50,810 shares of the company’s stock, valued at approximately $1,951,612.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $38.42, for a total transaction of $196,441.46. Following the transaction, the senior vice president now directly owns 57,918 shares in the company, valued at approximately $2,225,209.56. The disclosure for this sale can be found here. Insiders have sold a total of 66,578 shares of company stock worth $2,518,117 in the last three months. 3.90% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Acceleron Pharma (XLRN) Receives News Sentiment Rating of 0.10” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/acceleron-pharma-xlrn-receives-news-sentiment-rating-of-0-10.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.